With complements: C3 inhibition in the clinic
Authors:
- 25 September 2022
- journal article
- review article
- Published by Wiley in Immunological Reviews
- Vol. 313 (1) , 358-375
Abstract
Summary: C3 is a key complement protein, located at the nexus of all complement activation pathways. Extracellular, tissue, cell‐derived, and intracellular C3 plays critical roles in the immune response that is dysregulated in many diseases, making it an attractive therapeutic target. However, challenges such as very high concentration in blood, increased acute expression, and the elevated risk of infections have historically posed significant challenges in the development of C3‐targeted therapeutics. This is further complicated because C3 activation fragments and their receptors trigger a complex network of downstream effects; therefore, a clear understanding of these is needed to provide context for a better understanding of the mechanism of action (MoA) of C3 inhibitors, such as pegcetacoplan. Because of C3's differential upstream position to C5 in the complement cascade, there are mechanistic differences between pegcetacoplan and eculizumab that determine their efficacy in patients with paroxysmal nocturnal hemoglobinuria. In this review, we compare the MoA of pegcetacoplan and eculizumab in paroxysmal nocturnal hemoglobinuria and discuss the complement‐mediated disease that might be amenable to C3 inhibition. We further discuss the current state and outlook for C3‐targeted therapeutics and provide our perspective on which diseases might be the next success stories in the C3 therapeutics journey.Keywords
This publication has 123 references indexed in Scilit:
- Increased serum complement C3 and C4 concentrations and their relation to severity of chronic spontaneous urticaria and CRP concentrationJournal of Inflammation, 2013
- Anti-VEGF Treatment Strategies for Wet AMDJournal of Ophthalmology, 2012
- Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway–mediated diseasesBlood, 2011
- Ligation of CD46 to CD40 inhibits CD40 signaling in B cellsInternational Immunology, 2011
- Infections of People with Complement Deficiencies and Patients Who Have Undergone SplenectomyClinical Microbiology Reviews, 2010
- Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitorNature Immunology, 2009
- Modulation of the antitumor immune response by complementNature Immunology, 2008
- Locally produced C5a binds to T cell–expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosisBlood, 2008
- Locally Produced Complement Fragments C5a and C3a Provide Both Costimulatory and Survival Signals to Naive CD4+ T CellsImmunity, 2008
- Factor H–mediated cell surface protection from complement is critical for the survival of PNH erythrocytesBlood, 2007